Rechercher des projets européens

Plus de 40 projets européens trouvés

Recherche sur 125080 projets européens

 TERMINÉ 

Human Puripotent Stem Cell Registry (hPSCreg)

Date du début: 1 janv. 2017, Date de fin: 31 déc. 2021,

European registry for human embryonic stem cell lines
Voir le projet

 2

 TERMINÉ 

Prenatal Stress and Programming of Newborn and Infant Telomere Biology and Cellular Aging (PrenatStressAging)

Date du début: 1 oct. 2016, Date de fin: 30 sept. 2021,

The long-term consequences of exposure to excess stress on the initiation and progression of many age-related diseases are well established. The period of intrauterine life represents among the most sensitive developmental windows, at which time the effects of stress may be transmitted inter-generationally from a mother to her as-yet-unborn child. The elucidation of mechanisms underlying such effe ...
Voir le projet

 1

 TERMINÉ 

Personalized whole brain simulations: linking connectomics and dynamics in the human brain (BrainModes)

Date du début: 1 août 2016, Date de fin: 31 juil. 2021,

Background. We have detailed maps of brain structure and function, yet are lacking understanding of how the highly connected units interact and give rise to mental processes. The Virtual Brain (TVB), a whole brain simulation framework, aims to bridge that gap. Yet it is still developing. We are proposing here breakthrough advances that reveal mechanisms of brain function and foster collaboration b ...
Voir le projet

 1

 TERMINÉ 

BIOlogical therapy CYCLEs towards tailored, needs-driven, safer and cost-effective management of Crohn’s disease (BIOCYCLE)

Date du début: 1 avr. 2015, Date de fin: 31 mars 2021,

"The BIOCYCLE Project proposes to test and critically assess the benefits and risks of an innovative regimen for improving the treatment of Crohn’s disease (CD), a chronic immune-mediated inflammatory disease affecting the gastro-intestinal tract of an increasing number of patients. Currently, the combination of anti-TNFα monoclonal antibodies and immunosuppressants used without interruption is th ...
Voir le projet

 13

 TERMINÉ 

A multicenter phase IIb study using HLA-unmatched allogeneic placenta-derived stromal cells (PLX-PAD) for the treatment of severe critical limb ischemia accompanied by mechanistic studies (PACE)

Date du début: 1 janv. 2017, Date de fin: 31 déc. 2020,

PACE aims to transform the treatment of patients suffering from critical limb ischemia (CLI), a disease with high medical need, because of limited treatment options and poor outcome by applying a novel, off-the-shelf allogeneic placenta-derived stromal cell product (PLX-PAD). Despite improvements in medical care and revascularization, patients with CLI continue to have a high risk of major amputat ...
Voir le projet

 9

 TERMINÉ 

Transgenerational transmission of maternal childhood trauma and its sequelae – Altered maternal physiology during pregnancy and implications for newborn neurodevelopment (TransCTNeurodev)

Date du début: 1 nov. 2015, Date de fin: 31 oct. 2020,

Alarming statistics in a recent report by the EU Agency for Fundamental Rights suggest that 1 in 3 women have experienced physical or sexual violence in childhood. The sequelae of childhood trauma (CT) exposure include psychopathology, altered stress physiology, obesity, and increased likelihood of exposure to violence in adulthood. Also, emerging evidence suggests the long shadow cast by CT may b ...
Voir le projet

 1

 TERMINÉ 

IMMUNOBIOLOGY OF LYMPHOID STROMAL CELLS (STROMA)

Date du début: 1 oct. 2015, Date de fin: 30 sept. 2020,

In 1984, Nossal wrote ‘‘A readership consisting of primarily anatomists has every right to question the favorite sport of research workers in cell immunology. This is to take a lymphoid tissue and totally destroy its beautiful and elaborately designed architecture to obtain simple cell suspension of lymphocytes, which are then asked to do more or less all the jobs of the original anatomic masterpi ...
Voir le projet

 2

 TERMINÉ 

A Clinical Decision Support system based on Quantitative multimodal brain MRI for personalized treatment in neurological and psychiatric disorders (CDS-QUAMRI)

Date du début: 1 sept. 2015, Date de fin: 31 août 2020,

A large number of neurological and psychiatric disorders lack objective criteria for primary diagnoses, early differential diagnosis with regard to subtypes in treatment response and disease progression or effective therapy monitoring resulting in a tremendous negative socio-economic impact. Scientific studies based on advanced MRI methods indicate that related patients show specific subtle change ...
Voir le projet

 7

 TERMINÉ 

Comparing the effectiveness and safety of additional low-dose glucocorticoid in treatment strategies for elderly patients with rheumatoid arthritis (GLORIA)

Date du début: 1 sept. 2015, Date de fin: 31 août 2020,

GLORIA aims to prove that the addition of chronic low dose glucocorticoids (GC) to current antirheumatic therapy is highly cost-effective and safe in elderly patients with rheumatoid arthritis (RA). RA is a frequent (affecting > 2% of the elderly population), painful and disabling chronic disease with high societal costs. RA is associated with multiple comorbidities, polypharmacy and adverse event ...
Voir le projet

 13

 TERMINÉ 

HARMONIzation and integrative analysis of regional, national and international Cohorts on primary Sjögren’s Syndrome (pSS) towards improved stratification, treatment and health policy making (HarmonicSS)

Date du début: 1 janv. 2017, Date de fin: 30 juin 2020,

HarmonicSS vision is to create an International Network and Alliance of partners and cohorts, entrusted with the mission of addressing the unmet needs in primary Sjogren Syndrome; working together to create and maintain a platform with open standards and tools, designed to enable secure storage, governance, analytics, access control and controlled sharing of information at multiple levels along wi ...
Voir le projet

 39

 TERMINÉ 

Secondary prEvention of CardiovascUlaR disease in the Elderly trial (SECURE)

Date du début: 1 mai 2015, Date de fin: 30 avr. 2020,

While Cardiovascular diseases (CVD) are the main cause of death worldwide, they are responsible for half of all deaths in Europe. The overall ageing of the European population and improving survival of patients with coronary heart disease has created a large population of older adults eligible for secondary prevention. Despite the established efficacy of cardiovascular medications, suboptimal adhe ...
Voir le projet

 13

 TERMINÉ 

A multi-center randomized, placebo-controlled trial of mirabegron, a new beta3-adrenergic receptor agonist on left ventricular mass and diastolic function in patients with structural heart disease (BETA3_LVH)

Date du début: 1 mai 2015, Date de fin: 30 avr. 2020,

Patients with cardiovascular risk factors, e.g. hypertension and obesity are at risk of developing heart failure with preserved ejection fraction (HFpEF), a highly prevalent disease in the elderly, mostly women population. There is currently no specific, defined treatment for HFpEF, beyond control of risk factors. Activation of cardiac and vascular Beta3-adrenergic receptors (B3AR) represents a ne ...
Voir le projet

 15

 TERMINÉ 

Collaborative European NeuroTrauma Effectiveness Research in TBI (CENTER-TBI)

Date du début: 1 oct. 2013, Date de fin: 31 mars 2020,

Traumatic Brain Injury (TBI) is a major cause of death and disability, leading to great personal suffering to victim and relatives, as well as huge direct and indirect costs to society. Strong ethical, medical, social and health economic reasons therefore exist for improving treatment. The CENTER-TBI project will collect a prospective, contemporary, highly granular, observational dataset of 5400 p ...
Voir le projet

 44

 TERMINÉ 

Cancer treatment and monitoring through identification of circulating tumour cells and tumour related nucleic acids in blood (CANCER-ID)

Date du début: 1 janv. 2015, Date de fin: 31 déc. 2019,

Blood-based biomarkers such as Circulating Tumor Cells (CTCs), circulating free tumor DNA (cfDNA) and microRNAs (miRNAs) have the potential to improve the development of personalized medicines for cancer patients. This is of particular importance when biopsies of the primary tumor or metastases are not accessible (e.g. at early disease stages or in minimal residual disease) or possible and the ass ...
Voir le projet

 34

 TERMINÉ 

Imaging the Force of Cancer (FORCE)

Date du début: 1 janv. 2016, Date de fin: 31 déc. 2019,

Cancer is the second leading cause of mortality in EU member states with ~90% of all cancer deaths caused by metastatic spread. Despite its significance, measuring metastatic potential as well as potential indicators of therapy efficacy remain unmet clinical challenges. Recently, it has been demonstrated in vitro, that aggressive metastatic cells pull on their surroundings suggesting that metastat ...
Voir le projet

 18

 TERMINÉ 

Molecular Mechanisms of Endometriosis (MOMENDO)

Date du début: 1 janv. 2016, Date de fin: 31 déc. 2019,

Endometriosis (the presence of endometrial-like tissue or ‘lesions’ outside the uterus) is a chronic inflammatory disease affecting 6-10% of reproductive age women. It is associated with pelvic pain, painful periods, pain with sexual intercourse, and subfertility. The socioeconomic impacts of endometriosis are considerable. The recent WERF EndoCost study (a worldwide cost-of-illness study) reporte ...
Voir le projet

 6

 TERMINÉ 

Video Optical See-Through Augmented Reality surgical System (VOSTARS)

Date du début: 1 déc. 2016, Date de fin: 30 nov. 2019,

The idea of integrating the surgeon’s perceptive efficiency with the aid of new augmented reality (AR) visualization modalities has become a dominant topic of academic and industrial research in the medical domain since the 90’s. AR technology appeared to represent a significant development in the context of image-guided surgery (IGS).The quality of the AR experience affects the degree of acceptan ...
Voir le projet

 11

 TERMINÉ 

MesopOrous matrices for localiZed pH-triggered releAse of theRapeuTic ions and drugs (MOZART)

Date du début: 1 nov. 2015, Date de fin: 31 oct. 2019,

The concept behind MOZART is to develop a library of inorganic nanomatrices to be used as smart platforms for effective, non-invasive and highly targeted therapies. MOZART will address, as proof of concept, nanomatrices to treat delayed bone healing and non-healing chronic skin wounds, which are both characterised by an inflammation and often infection. Mesoporous therapeutic glasses (MTGs), doped ...
Voir le projet

 11

 TERMINÉ 

ALK Activation as a target of TRAanslational Science (ALKATRAS): Break free from cancer (ALKATRAS)

Date du début: 1 sept. 2015, Date de fin: 31 août 2019,

This ETN is embedded into an established international research programme; The European Research Initiative on Anaplastic Lymphoma Kinase (ALK)-related malignancies (ERIA; www.erialcl.net) is an existing and functional network of 13 partners, which will cosset and nurture a cohort of early stage researchers to become confident, competent, independent and well-connected European scientists with exc ...
Voir le projet

 13

 TERMINÉ 

BIOactive implantable CApsule for PANcreatic islets immunosuppression free therapy (BIOCAPAN)

Date du début: 1 juin 2015, Date de fin: 31 mai 2019,

The key therapeutic issue in diabetes mellitus type I and II is glycaemic control. Reductions of constant self-control, of insulin injections, and of long-term complications would have tremendous benefit for quality of life. The best therapy option is the transplantation of allogeneic islet cells, but the current state of the art limits the applicability of this approach. Implanting unprotected gr ...
Voir le projet

 10

 TERMINÉ 

A drug strategy targeting stabilised mutant p53 to fight metastatic platinum-resistant ovarian cancer (GANNET53)

Date du début: 1 oct. 2013, Date de fin: 31 mars 2019,

"Epithelial ovarian cancer (EOC) is the most lethal gyncaecological malignancy causing 41900 deaths annually in Europe. The predominance of aggressive Type II tumours, which are characterised by a high frequency of p53 mutations, and primary or acquired resistance to platinum-based chemotherapy profoundly contribute to the high mortality rate. With current standard therapy the median overall survi ...
Voir le projet

 20

 TERMINÉ 

Adverse Immune Signatures and their Prevention in Corneal Transplantation (VISICORT)

Date du début: 1 avr. 2014, Date de fin: 31 mars 2019,

"Immune system response is the most complex barrier to long-term success of tissue transplants/implants from allogeneic and bio-artificial sources. While newly developed tissue transplant procedures are not yet performed frequently enough for robust analysis of adverse immune responses in humans, corneal transplantation (CT) is a well-established allogeneic tissue transplant with >100,000 full- an ...
Voir le projet

 12

 TERMINÉ 

Diagnostic Imaging Strategies for Patients with Stable Chest Pain and Intermediate Risk of Coronary Artery Disease: Comparative Effectiveness Research of Existing Technologies (DISCHARGE)

Date du début: 1 févr. 2014, Date de fin: 31 janv. 2019,

Coronary artery disease (CAD) is the leading cause of death in high-income countries. Invasive coronary angiography (ICA) is the reference standard for the diagnosis of CAD and allows immediate therapy. However, only 40% of patients undergoing ICA actually have obstructive CAD and ICA has relatively rare but considerable risks. Coronary computed tomography (CT) is the most accurate diagnostic test ...
Voir le projet

 38

 TERMINÉ 

Heart OMics in AGEing (HOMAGE)

Date du début: 1 févr. 2013, Date de fin: 31 janv. 2019,

As more people survive into old age, the prevalence of heart failure (HF), one of the most common and debilitating diseases in older people, will rise still further. Delaying or preventing HF will have great benefit to those at personal risk, their families, society and the economy. HOMAGE aims to provide a biomarker (BM) approach that will a) help identify i. patients at high risk of developing ...
Voir le projet

 22

 TERMINÉ 

Molecular Reclassification to Find Clinically Useful Biomarkers for Systemic Autoimmune Diseases (PRECISESADS)

Date du début: 1 févr. 2014, Date de fin: 31 janv. 2019,

We concur to the IMI on “Reclassification of SLE, connective tissue diseases and RA” call by presenting a proposal aimed at using the power of OMICs, and bioinformatics to identify new classifications for diseases known to share common pathophysiological mechanisms. Such knowledge has not been applied to individual patients, depriving them from potential benefits in terms of the use of new therape ...
Voir le projet

 30

 TERMINÉ 

Biomarker Development for Postoperative Cognitive Impairment in the Elderly (BioCog)

Date du début: 1 févr. 2014, Date de fin: 31 janv. 2019,

Postoperative delirium (POD) is characterized by the progressive deterioration of sensory/cognitive function after surgery with incidences of up to 30-80%. It is frequently followed by postoperative cognitive dysfunction (POCD) which tends to persist over time. In elderly patients, POCD resembles chronic dementia and appears to accelerate the cognitive decline in Alzheimer dementia. POD is strongl ...
Voir le projet

 12

 TERMINÉ 

Neuropathic pain: biomarkers and druggable targets within the endogenous analgesia system (NEUROPAIN)

Date du début: 1 janv. 2014, Date de fin: 31 déc. 2018,

Neuropathic pain has a high incidence in Europe and often affects the patient’s emotional balance and quality of life. Recent meta-analyses have shown that conventional analgesic drugs are not sufficiently effective in these patients and are limited by serious side effects. The search for new analgesics is extremely difficult despite identification of several new potential targets and enormous inv ...
Voir le projet

 12

 TERMINÉ 

Long-term, prospective study evaluating clinical and molecular biomarkers of epileptogenesis in a genetic model of epilepsy – tuberous sclerosis complex (EPISTOP)

Date du début: 1 nov. 2013, Date de fin: 31 oct. 2018,

Despite a great progress in the management of epilepsy, still one third of patients is refractory to available medications. The incidence of epilepsy is highest in infancy and 50% of children experience epilepsy-related comorbidities, such as developmental delay and autism. The development of epilepsy (epileptogenesis), extensively studied in animals, is barely studied in humans, as patients usual ...
Voir le projet

 16

 TERMINÉ 

PanCare Studies in Fertility and Ototoxicity to Improve Quality of Life after Cancer during Childhood, Adolescence and Young Adulthood (PANCARELIFE)

Date du début: 1 nov. 2013, Date de fin: 31 oct. 2018,

Survival rates after childhood cancer now reach nearly 80% in developed European countries as a result of more effective therapies and better supportive care, leading to a steady increase in the number of survivors in the population. However, the treatments that have improved survival are harsh and cause serious side-effects that can greatly impact survivors’ quality of life in the long term. The ...
Voir le projet

 19

 TERMINÉ 

Development and Epilepsy - Strategies for Innovative Research to improve diagnosis, prevention and treatment in children with difficult to treat Epilepsy (DESIRE)

Date du début: 1 oct. 2013, Date de fin: 30 sept. 2018,

DESIRE will focus on epileptogenic developmental disorders EDD, i.e. early onset epilepsies whose origin is closely related to developmental brain processes. A major cause of EDD are malformations of cortical development (MCD), either macroscopic or subtle. EDD are often manifested as epileptic encephalopathies (EE), i.e. conditions in which epileptic activity itself may contribute to severe cogni ...
Voir le projet

 29

 TERMINÉ 

Treating stroke with Affibody molecules targeting the inflammatory mediator HMGB1 (COUNTERSTROKE)

Date du début: 1 oct. 2013, Date de fin: 30 sept. 2018,

The scope of the project is to generate a candidate drug targeting the inflammatory mediator High mobility group box 1 protein (HMGB1) to be used in treatment of stroke. The candidate drug will be validated in animal models, characterized and optimized for subsequent clinical development.Stroke remains a leading cause of death and disability throughout the world. Within EU, more than 500 000 perso ...
Voir le projet

 6

 TERMINÉ 

Systems biology for the functional validation of genetic determinants of skeletal diseases (SYBIL)

Date du début: 1 oct. 2013, Date de fin: 30 sept. 2018,

"The aim of SYBIL is to carry out extensive functional validation of the genetic determinants of rare and common skeletal diseases and the age related factors contributing to these painful conditions. To achieve this goal SYBIL will gather complementary translational and transnational scientists, systems biologists, disease modellers, leading SMEs and industrialists that will perform in-depth char ...
Voir le projet

 19

 TERMINÉ 

implementAtion anD OPeration of the gateway for healTh into BBMRI-ERIC (ADOPT BBMRI-ERIC)

Date du début: 1 oct. 2015, Date de fin: 30 sept. 2018,

"BBMRI-ERIC: the Biobanking and BioMolecular resources Research Infrastructure - European Research Infrastructure Consortium, aims to establish, operate and develop a Pan-European distributed research infrastructure in order to facilitate the access to biological resources as well as facilities and to support high quality biomolecular and biomedical research. The ADOPT BBMRI-ERIC proposal aims at ...
Voir le projet

 22

 TERMINÉ 

Personalized diagnosis and treatment of hyperinsulinemic hypoglycaemia caused by beta-cell pathology (BETACURE)

Date du début: 1 avr. 2014, Date de fin: 31 mars 2018,

Background:Hyperinsulinaemic hypoglycaemia (HH) is a potentially lethal disease caused by over functioning beta cells derived from the pancreatic islets of Langerhans. Lethal HH and brain damage is a problem especially in infants with congenital HH. Current therapeutic approaches are associated with severe side effects/morbidity (diabetes, exocrine pancreas insufficiency etc.) considered acceptabl ...
Voir le projet

 17

 TERMINÉ 

Automation of Flow Cytometric Analysis for Quality-Assured Follow-up Assessment to Guide Curative Therapy for Acute Lymphoblastic Leukaemia in Children (AutoFlow)

Date du début: 1 févr. 2014, Date de fin: 31 janv. 2018,

Acute Lymphoblastic Leukaemia is the most frequent leukaemia entity in children and adolescents. Despite continued progress and refinement of therapeutic approaches, disease relapse due to insufficient extinction of leukaemic blasts still remains the number one cause of treatment failure. About 15-20% of paediatric patients with the disease still suffer from relapse. Flow cytometry (FCM) is one of ...
Voir le projet

 5

 TERMINÉ 

Systems Biology to Identify Molecular Targets for Vascular Disease Treatment (SYSVASC)

Date du début: 1 févr. 2014, Date de fin: 31 janv. 2018,

Asymptomatic vascular damage accumulates for years before patients are identified and subjected to therapeutic measures. The limited knowledge on early vascular disease pathophysiology is reflected in the lack of therapeutic options. SysVasc aims to overcome this limitation by mounting a comprehensive systems medicine approach to elucidate pathological mechanisms, which will yield molecular target ...
Voir le projet

 19

 TERMINÉ 

Proteomic prediction and Renin angiotensin aldosterone system Inhibition prevention Of early diabetic nephRopathy In TYpe 2 diabetic patients with normoalbuminuria (PRIORITY)

Date du début: 1 janv. 2012, Date de fin: 31 déc. 2017,

Patients with diabetes are at risk of developing diabetic nephropathy, which will ultimately result in the requirement for renal replacement therapy and is also associated with high cardiovascular morbidity and mortality. Detection of low concentrations of albuminuria in urine (microalbuminuria) is the current clinical standard for detecting those at significant risk and targeting preventive treat ...
Voir le projet

 21

 TERMINÉ 

Efficacy and safety of MRI-based thrombolysis in wake-up stroke: a randomised, double-blind, placebo-controlled trial (WAKE-UP)

Date du début: 1 déc. 2011, Date de fin: 30 nov. 2017,

WAKE-UP is an investigator-initiated, multicentre, randomised, double-blind, placebo-controlled trial designed to test efficacy and safety of MRI-based intravenous thrombolysis in patients with wake-up stroke. Every year 1.5 million patients suffer a stroke in the EU. Up to 20% of stroke patients wake up with stroke symptoms. Currently these patients are excluded from thrombolysis which is the onl ...
Voir le projet

 13

 TERMINÉ 

Personalized diagnostics and treatment of high risk coronary artery disease patients (RISKYCAD)

Date du début: 1 nov. 2012, Date de fin: 31 oct. 2017,

Although the accurate diagnosis and prevention of coronary artery disease (CAD), acute myocardial infarction (AMI) and death is a major public health issue, risk stratification for CAD with current diagnostic tools is not properly supporting clinical decision making. RiskyCAD’s overall goal is to identify novel biomarkers for asymptomatic patients in high risk of major coronary events, and develop ...
Voir le projet

 12

 TERMINÉ 

Personalized minimization of immunosuppression after solid organ transplantation by biomarker-driven stratification of patients to improve long-term outcome and health-economic data of transplantation (BIO-DrIM)

Date du début: 1 nov. 2012, Date de fin: 31 oct. 2017,

Organ transplantation has emerged as the “gold standard” therapy for end-stage organ failure. Incomplete control of chronic allograft injury but also the adverse effects of long-term immunosuppression (IS) continue to challenge the long-term success of transplantation. The paradigm is shifting from increasing “net”-IS by novel drugs to the concept of minimizing long-term IS as early as possible. H ...
Voir le projet

 17